Emobot in the news.

A chronological record of press coverage, interviews, broadcasts, and research features — from IEEE ICASSP 2024 to the late-breaking ASCP 2026 poster co-authored with NRx Pharmaceuticals and Johns Hopkins.

16 featuresASCP · GlobeNewswire · Le Quotidien du Médecin · Sciences et Avenir · BFM · Euronews2024 → 2026

Featured

Recent milestones

ResearchMay 27, 2026· ASCP 2026 · American Society of Clinical Psychopharmacology · Emobot × NRx Pharmaceuticals

NRx Pharmaceuticals (Nasdaq: NRXP) strategic partner Emobot presents late-breaking clinical validation of EMOCARE at ASCP 2026

Late-breaking poster presented by Tanel Petelot at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology. First public pooled clinical validation of EMOCARE — Emobot's passive, multimodal, smartphone-based Depression Thermometer — across three prospective observational studies (n = 45). Within-person concordance vs. clinician-rated MADRS reached r = 0.895 (p = .016); sensitivity to symptom change vs. PHQ-9 reached ρ = 0.834 (p < .001). Co-authored with NRx Pharmaceuticals, CentraleSupélec and Johns Hopkins.

Read the announcement →
Press releaseMarch 30, 2026· GlobeNewswire · BioSpace · Yahoo Finance · Barchart

Hope Therapeutics (NRx Pharmaceuticals, Nasdaq: NRXP) announces strategic partnership with Emobot

Hope Therapeutics — a subsidiary of NRx Pharmaceuticals — will deploy Emobot's AI-powered Depression Thermometer across its interventional psychiatry clinic network. The first large-scale clinical integration of Emobot's passive monitoring platform for treatment-resistant depression.

Read the announcement →
Press releaseMarch 11, 2026· Emobot × GHU Paris Psychiatrie & Neurosciences

Emobot and GHU Paris announce research partnership for the COGPSY study

Emobot and GHU Paris Psychiatrie & Neurosciences — the leading French and European hospital group dedicated to psychiatry and neurosciences — signed a strategic scientific partnership within the COGPSY study, coordinated by Pr. Fabien Vinckier and Dr. Jacob Dhoté. The goal: integrate Emobot's multimodal digital biomarkers to characterize cognitive and emotional alterations in patients receiving rapid-acting treatments like esketamine (Spravato®).

Read the announcement →

Timeline

Newest first

2026

4 features

ResearchMay 27, 2026EN

Outlet: ASCP 2026 · American Society of Clinical Psychopharmacology · Emobot × NRx Pharmaceuticals

NRx Pharmaceuticals (Nasdaq: NRXP) strategic partner Emobot presents late-breaking clinical validation of EMOCARE at ASCP 2026

Late-breaking poster presented by Tanel Petelot at the 2026 Annual Meeting of the American Society of Clinical Psychopharmacology. First public pooled clinical validation of EMOCARE — Emobot's passive, multimodal, smartphone-based Depression Thermometer — across three prospective observational studies (n = 45). Within-person concordance vs. clinician-rated MADRS reached r = 0.895 (p = .016); sensitivity to symptom change vs. PHQ-9 reached ρ = 0.834 (p < .001). Co-authored with NRx Pharmaceuticals, CentraleSupélec and Johns Hopkins.

Read / watch →
Press releaseMarch 30, 2026EN

Outlet: GlobeNewswire · BioSpace · Yahoo Finance · Barchart

Hope Therapeutics (NRx Pharmaceuticals, Nasdaq: NRXP) announces strategic partnership with Emobot

Hope Therapeutics — a subsidiary of NRx Pharmaceuticals — will deploy Emobot's AI-powered Depression Thermometer across its interventional psychiatry clinic network. The first large-scale clinical integration of Emobot's passive monitoring platform for treatment-resistant depression.

Read / watch →
Press releaseMarch 11, 2026EN

Outlet: Emobot × GHU Paris Psychiatrie & Neurosciences

Emobot and GHU Paris announce research partnership for the COGPSY study

Emobot and GHU Paris Psychiatrie & Neurosciences — the leading French and European hospital group dedicated to psychiatry and neurosciences — signed a strategic scientific partnership within the COGPSY study, coordinated by Pr. Fabien Vinckier and Dr. Jacob Dhoté. The goal: integrate Emobot's multimodal digital biomarkers to characterize cognitive and emotional alterations in patients receiving rapid-acting treatments like esketamine (Spravato®).

Read / watch →
Conference talkJanuary 11, 2026EN

Outlet: Rapid Acting Mental Health Treatment (RAMHT) · JPM 2026

Panel: AI-Enablement in Practice Development, Enhanced Care Delivery, Patient Screening and Monitoring

At JPM 2026, Tanel Petelot joined a RAMHT panel on AI in interventional psychiatry alongside Jonathan Seltzer (SimplePractice), Dominik Middelmann (mdhub), and Edwin Wong (Psyrin), moderated by Grady Hannah (Attentio / NightWare / RAMHT). The discussion focused on how AI is reshaping practice operations, care delivery, and continuous patient monitoring for IP clinics.

Read / watch →
2025

9 features

BroadcastNovember 22, 2025FR

Outlet: BFM Business · Check-up Santé (Fabien Guez)

Tanel Petelot sur BFM Business pour parler santé mentale et psychiatrie

On BFM Business's Check-up Santé (hosted by Fabien Guez), Tanel Petelot laid out the gap between periodic psychiatric assessments and what patients actually experience between visits — and how Emobot's passive smartphone monitoring is designed to close it.

Read / watch →
Feature articleNovember 2025FR

Outlet: Sciences et Avenir

Une IA pour suivre les variations d'humeur des patients dépressifs et bipolaires

Sciences et Avenir profiled Emobot's smartphone-based passive mood monitoring, with commentary from Pr. Fabien Vinckier (GHU Paris, Université Paris Cité, Institut du Cerveau) on how early detection of abnormal emotional variance between visits could be "very useful" for clinicians managing bipolar and depressed patients.

Read / watch →
Press releaseOctober 2025FR

Outlet: Pfizer France · WILCO

Emobot selected for Season 5 of the Pfizer Healthcare Hub France

Pfizer France and WILCO selected Emobot as one of six startups for the 5th edition of the Pfizer Healthcare Hub France — a 9-month acceleration program. The collaboration extends Emobot's mood-monitoring platform to the follow-up of depression associated with chronic inflammatory diseases (MICI, psoriasis), opening a new indication beyond interventional psychiatry.

Read / watch →
Feature articleSeptember 16, 2025FR

Outlet: Le Quotidien du Médecin (Aude Frapin)

Emobot : une IA pour suivre les variations d'humeur des patients dépressifs et bipolaires

In Le Quotidien du Médecin — France's reference daily for physicians — journalist Aude Frapin covered Emobot as a passive, smartphone-based mood monitor ("podomètre de l'humeur") designed to help psychiatrists catch relapse between the average 30-minute visit every two months, with a 120-doctor waiting list and 300+ patients already tracked.

Read / watch →
Press releaseSeptember 8, 2025FR

Outlet: Ministère de la Santé · France 2030

France 2030 : Emobot parmi les 3 lauréats de l'appel à projets « Dispositifs médicaux numériques en santé mentale »

Minister Yannick Neuder named Emobot one of three national winners of the France 2030 call for projects on digital medical devices in mental health. The award funds the REMOOD clinical trial — designed to establish the clinical efficacy of Emobot's passive mood-monitoring device and to support the CE marking pathway.

Read / watch →
Feature articleJuly 5, 2025EN

Outlet: VivaTech

6 Unmissable Startups at VivaTech 2025

VivaTech named Emobot one of six unmissable startups at its 2025 edition, highlighting the French-American company's AI-powered continuous mood monitoring and personalized digital therapy for the 280 million people living with mood disorders.

Read / watch →
BroadcastJune 12, 2025EN

Outlet: Euronews

VivaTech: Mental health innovations take centre stage at Europe's largest tech fair

Euronews profiled Emobot at VivaTech 2025 as a French startup using AI to monitor mood disorders via smartphone throughout the day — what co-founder Antony Perzo described on camera as "a sort of thermometer for mental health."

Read / watch →
InterviewApril 8, 2025FR

Outlet: Who's Who

5 Questions à Tanel Petelot (Emobot)

In the Who's Who founder interview series, Tanel Petelot answered five questions on Emobot's origin story, product vision, and the road from CentraleSupélec to deployment across US interventional psychiatry clinics.

Read / watch →
ResearchJanuary 2025EN

Outlet: ICLR 2025

Emobot research accepted at ICLR 2025 (A* Conference)

Work from the Emobot research team on representation learning was accepted at the International Conference on Learning Representations — one of the three most selective AI research conferences in the world.

Read / watch →
2024

3 features

ResearchDecember 2024EN

Outlet: ASSTA SST 2024

Symptom-level depression prediction from speech — ASSTA SST 2024

Emobot researchers presented a method for predicting individual depressive symptoms directly from speech signal at ASSTA SST 2024, extending the company's multimodal pipeline beyond composite severity scores.

Read / watch →
InterviewOctober 2024FR

Outlet: L'Oeil de la E-Santé

Emobot: révolutionner le diagnostic dépressif grâce à l'IA et la thérapie digitale

At BIG 2024, L'Oeil de la E-Santé interviewed CTO and co-founder Antony Perzo on how Emobot replaces century-old paper questionnaires with AI analysis of facial and vocal expression, and feeds a clinician dashboard for remote symptom tracking between visits.

Read / watch →
ResearchApril 2024EN

Outlet: IEEE ICASSP 2024

Towards Improving Speech Emotion Recognition Using Synthetic Data Augmentation

Emobot's first paper was accepted at IEEE ICASSP 2024, the flagship conference on signal processing — introducing a synthetic data augmentation method (via emotion conversion) to improve speech emotion recognition.

Read / watch →

Missing something?

We update this page whenever Emobot is covered in the press or when a new peer-reviewed paper is released. Journalists, producers and analysts — see the press-inquiries block below.

Press inquiries

Talk to Tanel.

For interview requests, commentary, or access to clinical data, Tanel Petelot (CEO & co-founder) is the primary contact. DM is the fastest channel.

DM Tanel on LinkedIn →

Research

See the peer-reviewed work.

Every headline stat on this site — MADRS r=0.895, PHQ-9 Δ ρ=0.834 — traces back to a specific publication. The full ASCP 2026 poster is on /articles.

Scientific articles →

Or see the dashboard in action — a 30-minute walkthrough.